The LYCRA Company Showcases Denim Innovations at Kingpins New York
18.7.2022 12:00:00 EEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, is exhibiting its latest products for denim in person at Kingpins New York July 20-21 at Pier 36 in New York City. The company is showcasing samples made with LYCRA® ADAPTIV fiber, LYCRA® DUAL COMFORT technology, and its other industry-leading denim fibers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005067/en/
The LYCRA Company showcases denim innovations at Kingpins NYC. (Photo: Business Wire)
LYCRA® ADAPTIV fiber is a patent-pending revolutionary fiber that creates "one-size-fits-more" garments that adapt to fit different body shapes within a size. It also delivers a second-skin effect with excellent recovery and comfortable holding power.
"Consumers have different body types and this can impact garment fit and comfort," said Rita Ratskoff, senior strategic manager - denim, The LYCRA Company. "By offering greater shape tolerance, LYCRA® ADAPTIV fiber has the potential to reduce apparel returns and manufacturing waste by enabling the undercutting of patterns."
LYCRA® DUAL COMFORT technology combines the comfortable fit of stretch fabrics, the cool and dry comfort of moisture management, and LYCRA® T400® A EcoMade fiber, made from 68% sustainable resources including recycled and renewable content.
In The LYCRA Company booth, show visitors can also find innovative denim solutions from the LYCRA® XTRA LIFE™ brand's family of innovative denim solutions, including LYCRA® Anti-Slip fiber, LYCRA® dualFX® technology, and LYCRA® T400® fiber. They create long-lasting, durable garments that enable designers to develop heavy wash downs and distressed looks without fear.
For garment makers seeking sustainable offerings that reduce waste, denim that uses recycled materials will be on display. LYCRA® EcoMade fiber contains 20 percent recycled content, and COOLMAX® and THERMOLITE® EcoMade technologies are made from 100% textile waste.
"The LYCRA Company is committed to developing an innovative range of sustainable solutions made with renewable and recycled content that will enhance the performance of our customers' offerings while minimizing their environmental impact," said Jean Hegedus, sustainability director, The LYCRA Company. "We are excited to be in person at Kingpins again to promote our sustainable denim fibers that help reduce waste and set the stage for circularity."
Hegedus will join a panel discussion at Kingpins on July 21 at 11:30 a.m. entitled, "In Conversation: Denim Changemakers." This panel brings together representatives from companies in the United Nations Conscious Fashion and Lifestyle Network, whose members are accelerating change in the denim sector. Participants will discuss industry commitments to increase sustainable practices and advance collective action to reach the United Nations' Sustainable Development Goals.
Kingpins New York is an invitation-only event for the denim community at Pier 36 / Basketball City in Manhattan. For more information, visit kingpinsshow.com/shows/new-york/.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com.
LYCRA®, dualFX®, T400®, XTRA LIFE™, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005067/en/
Contact information
Kristin Altimari
kristin.altimari@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom